sGC Activator Therapy for Chronic Endothelial Dysfunction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for chronic vascular dysfunction associated with conditions like Chronic Fatigue Syndrome (ME/CFS) and Post COVID Syndrome are inadequate, failing to effectively address endothelial dysfunction and hypo-perfusion, which are underlying factors in these syndromes.

Innovation Solution

A pharmaceutical composition comprising a soluble guanylate cyclase (sGC) stimulator, such as vericiguat, is used to treat chronic vascular dysfunction by stimulating sGC activity, increasing cGMP levels, and reducing inflammation and endothelial dysfunction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for chronic vascular dysfunction are used, then treatment is provided, but the treatments fail to effectively address endothelial dysfunction and hypo-perfusion

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to address underlying factors

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by switching from conventional symptomatic treatments to a targeted molecular mechanism approach using soluble guanylate cyclase stimulators. This changes the therapeutic parameter from general symptom management to specific modulation of cGMP signaling pathway, thereby effectively addressing endothelial dysfunction and hypo-perfusion at their molecular level

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses soluble guanylate cyclase stimulators as intermediary substances that mediate between the administered drug and the target biological system. These stimulators act as intermediaries to enhance cGMP production, which then mediates the therapeutic effects on endothelial function and vascular perfusion, bridging the gap between treatment administration and physiological improvement

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If symptomatic treatments are used for ME/CFS and Post COVID Syndrome, then symptoms are addressed, but underlying vascular dysfunction and inflammation are not treated

Engineering Contradiction:

Improvesimplicity of treatment approachVSAvoidcomprehensiveness of treatment

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent applies universality by using soluble guanylate cyclase stimulators that simultaneously address multiple underlying mechanisms including endothelial dysfunction, inflammation, and hypo-perfusion. This single class of compounds performs multiple therapeutic functions, making the treatment both simple to administer and comprehensive in its approach to treating the root causes of ME/CFS and Post COVID Syndrome

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The treatment improves endothelial function, reduces inflammation, and alleviates symptoms of chronic vascular dysfunction, including fatigue and muscle weakness, in ME/CFS and Post COVID Syndrome patients.

Implementation Method 1

a soluble guanylate cyclase stimulator... for use in the treatment of a medical condition comprising a chronic vascular dysfunction

Methodology Applied

Scientific EffectEnzyme activation: Enzyme

Data Source

PatentUS20250387391A1A soluble guanylat cyclase activator for treating chronic vascular dysfunction

Publication Date: 2025.12.25 CHARITE UNIVS MEDIZIN BERLIN

AI summary

A pharmaceutical composition including a soluble guanylate cyclase stimulator or salt thereof for use in the treatment of a medical condition comprising a chronic vascular dysfunction occurring or persisting after onset of an infection in a human subject. In preferred embodiments, the pharmaceutical composition comprises a soluble guanylate cyclase stimulator or salt thereof, preferably vericiguat, for use in the treatment of a chronic vascular dysfunction associated with vascular constriction, endothelial dysfunction and/or hypo-perfusion.